Compare Flagstar Bank NA (FLG) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Flagstar Bank NA vs Incyte Corporation — how do they compare? Flagstar Bank NA trades at $11.26 (market cap $4.71B), while Incyte Corporation trades at $113.03 (market cap $22.85B). The key difference: Incyte Corporation is far larger — about 4.9× Flagstar Bank NA's market cap, and Flagstar Bank NA pays a 0.35% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Flagstar Bank NA for 21 Days and Incyte Corporation for 33 Days on average.
| FLG | INCY | |
|---|---|---|
Market Cap | $4.71B | $22.85B |
Volume | 7,410,589 | 1,927,029 |
Sector | Financials | Health |
52-Week High | $15.36 | $129.93 |
52-Week Low | $10.72 | $83.80 |
Typical Hold Time | 21 Days | 33 Days |
Enterprise Value | $15.25B | $18.35B |
Dividend Yield | 0.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLG trades at $11.21, down 0.8% with bearish technical signals despite recent earnings beats. The stock shows mixed fundamentals with a high P/E of 378.33 but attractive P/B of 0.62, while transitioning from a $177M loss in 2025 to profitability in 2026. Recent news highlights strategic partnerships and a $250M share repurchase program, though Q2 2026 earnings missed expectations.
Analyst consensus remains bullish with a $17.07 price target (60% buy ratings), offering significant upside potential. Key risks include volatile cash flows and competitive banking pressures. The current discount to book value and institutional support suggest long-term value if profitability trends continue.
Incyte (INCY) trades at $113.44, up 0.63% with a bullish technical signal despite mixed moving averages. The company shows strong fundamentals with 2025 revenue of $5.14B, net income of $1.29B, and impressive profitability margins (gross margin 92.62%, net margin 27.71%). Recent FDA approval for Atebrioz and pipeline expansion signal growth beyond JAKAFI. Valuation appears reasonable with P/E of 14.36 and P/S of 3.98.
Outlook remains positive with analyst consensus target of $132.43 (16.7% upside) and 52% buy ratings. Key opportunities include pipeline diversification and $4B sales target, while risks involve JAKAFI patent expiration post-2029 and competitive pressures. Strong cash flow generation ($1.41B operating CF) supports continued R&D investment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Flagstar Bank NA
Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.
Read more on FLG →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
